MSC therapy refers to the clinical use of mesenchymal stem/stromal cells (MSCs), which are "multi-purpose" cells that help repair tissue and calm abnormal immune responses. 

MSCs work mainly by regulating immune responses, reducing inflammation, and supporting tissue repair.

• Approved indications - steroid-refractory acute GVHD (SR-aGVHD)
  After a stem cell transplant, the donor’s immune cells can attack the patient’s body. This is called Graft versus Host Disease (GVHD). Steroids are the first treatment, but sometimes they don’t work well enough. MSC therapy works because MSCs can “calm down” the overactive immune cells that are causing the attack, without shutting down the entire immune system.

• For clinical-trial-stage indications, MSC therapy is being investigated in liver failure, osteoarticular diseases, and neurodegenerative diseases.

For the approved GVHD indication – Amimestrocel Injection:

• Patients aged 14 years and older with steroid-refractory acute GVHD with predominant gastrointestinal involvement.

For clinical-trial-stage regenerative medicine:

• Cases are subject to protocol eligibility, ethics approval, regulatory requirements and informed consent. Assessment is performed by Gleneagles’ Virtual Assessment Centre and the research team against the protocol.
• Gleneagles’ Research Team coordinates the patient journey from study assessment and informed consent through treatment and follow-up. Working closely with investigators, pharmacy and the wider clinical team, the Team supports study operations, regulatory and ethics requirements, treatment coordination, safety reporting and research governance in accordance with the approved study protocol.

For GVHD products:

• It is not suitable for people who are allergic to any ingredient.
  
• It is not approved for patients under 14 years old.
• If the patient is pregnant, breastfeeding, or elderly, the doctor will need to assess carefully because there is limited information.
• It must be given in a hospital by a trained medical team.

For clinical trials:

• The research team must check the full protocol
  

1. Specialist assessment and confirmation of eligibility
   The clinical team will review the patient’s diagnosis, previous treatments, current medications, overall clinical condition and other relevant information to determine suitability for MSC therapy.
2. Treatment planning and informed consent
   The treating doctor will discuss the treatment plan, potential benefits and risks, alternative treatment options and monitoring requirements with the patient before treatment.
3. Pre-treatment assessment and preparation
   Relevant clinical assessments and investigations will be completed before treatment. The healthcare team will confirm the prescribed MSC product, dose and administration plan and make the necessary arrangements for treatment.
4. MSC infusion
   The MSC product will be administered in the hospital by a trained healthcare team in accordance with the prescribed treatment regimen and applicable product and hospital requirements.
5. Monitoring during and after infusion
   The patient will be closely monitored during and after treatment for infusion-related reactions and other potential adverse effects. 
6. Follow-up and further treatment
   The clinical team will assess the patient’s response and overall condition after treatment. Further treatment and follow-up will be arranged according to the prescribed regimen and individual clinical response.

MSC therapy provides an additional treatment option for eligible patients with Steroid-Refractory Acute Graft-versus-Host Disease (SR-aGVHD). MSCs have immunomodulatory properties that may help regulate the abnormal immune response associated with GVHD. Individual treatment response may vary, and suitability should be assessed by the treating team.

Amimestrocel is an off-the-shelf, standardised product derived from human umbilical cord tissue. It does not require collection of the patient’s own cells. This means treatment can be initiated promptly once the patient is assessed as eligible, without the wait time associated with autologous cell manufacturing.

As a biological product, infusion-related reactions such as allergic reactions must be monitored during administration. The product must be used in a hospital with adequate monitoring and emergency facilities. When used with other immunosuppressants, close monitoring is advised due to potential interactions.

Clinical studies have provided safety information for amimestrocel. Patients will be monitored during and after administration in accordance with the approved product information and hospital protocol. Long-term safety information continues to be monitored. 

Potential risks include infusion-related reactions (such as allergic reactions), and as with any biological product, there is a theoretical risk of transmitting infectious agents and ectopic tissue formation. Long-term risks remain to be monitored through post-marketing surveillance.